TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 159 filers reported holding TURNING POINT THERAPEUTICS I in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $32,873,000 | +180.5% | 436,866 | +0.1% | 0.01% | +250.0% |
| Q1 2022 | $11,719,000 | -44.8% | 436,452 | -1.9% | 0.00% | -33.3% |
| Q4 2021 | $21,231,000 | -48.8% | 445,091 | -28.7% | 0.00% | -57.1% |
| Q3 2021 | $41,444,000 | -16.5% | 623,881 | -2.0% | 0.01% | -22.2% |
| Q2 2021 | $49,653,000 | +24.7% | 636,414 | +51.2% | 0.01% | +28.6% |
| Q1 2021 | $39,812,000 | -25.4% | 420,889 | -3.9% | 0.01% | -30.0% |
| Q4 2020 | $53,383,000 | +50.9% | 438,112 | +8.2% | 0.01% | +25.0% |
| Q3 2020 | $35,377,000 | +62.5% | 404,948 | +20.1% | 0.01% | +60.0% |
| Q2 2020 | $21,775,000 | +61.8% | 337,127 | +11.9% | 0.01% | +25.0% |
| Q1 2020 | $13,455,000 | -27.9% | 301,280 | +0.5% | 0.00% | 0.0% |
| Q4 2019 | $18,671,000 | +363.8% | 299,739 | +180.0% | 0.00% | +300.0% |
| Q3 2019 | $4,026,000 | +163.5% | 107,058 | +185.1% | 0.00% | – |
| Q2 2019 | $1,528,000 | – | 37,552 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 2,750,000 | $260,122,000 | 5.80% |
| Burrage Capital Management LLC | 72,164 | $6,826,000 | 5.53% |
| Consonance Capital Management LP | 450,396 | $42,603,000 | 4.54% |
| MPM BioImpact LLC | 269,186 | $25,462,000 | 3.20% |
| Orbimed Advisors | 2,361,327 | $223,358,000 | 2.09% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 81,541 | $7,711,000 | 2.04% |
| SECTORAL ASSET MANAGEMENT INC | 257,879 | $24,393,000 | 1.85% |
| Nicholas Investment Partners, LP | 218,847 | $20,701,000 | 1.44% |
| Logos Global Management LP | 140,000 | $13,243,000 | 1.29% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 16,741 | $1,584,000 | 0.86% |